Cargando…
Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
Immunotherapy, including therapeutic vaccines, is increasingly being developed for patients with high-grade glioma, and combinations of immunotherapies and synergy with standard of care are being investigated. In this regard, bevacizumab (BEV) has been shown to synergize with immunotherapy in precli...
Autores principales: | Boydell, Emma, Marinari, Eliana, Migliorini, Denis, Dietrich, Pierre-Yves, Patrikidou, Anna, Dutoit, Valérie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520681/ https://www.ncbi.nlm.nih.gov/pubmed/30986995 http://dx.doi.org/10.3390/cancers11040464 |
Ejemplares similares
-
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma
por: Dutoit, Valérie, et al.
Publicado: (2017) -
Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients
por: Dutoit, Valérie, et al.
Publicado: (2020) -
Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread
por: Marinari, Eliana, et al.
Publicado: (2021) -
Promise and challenges of peptide-poly: ICLC vaccines for adult and pediatric gliomas
por: Okada, Hideho, et al.
Publicado: (2013) -
Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma
por: Marinari, Eliana, et al.
Publicado: (2020)